Navigation Links
KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
Date:6/25/2008

spect to the continued listing of the Company's stock on the New York Stock Exchange; (16) risks that the Company may not ultimately prevail in litigation, including challenges to our intellectual property rights by actual or potential competitors or to our ability to market generic products due to brand company patents; (17) the possibility that KV's current estimate of the financial effect of certain previously announced product recalls could prove to be incorrect; (18) whether any of the product recalls result in litigation, agency action or material damages; and (19) the risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission.

This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.


'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2
...tors for SCAN Health,Plan Arizona and SCAN Long Te...Lescault as president of SCAN,s Arizona operations... health plan for Medicare and,Medicaid-eligible in.../www.newscom.com/cgi-bin/prnh/20080701/LATU551 ), ...
...Chief Financial Officer, OAKLAND, Calif., July 1 ...ldHeart" or the "Corporation") announced today,tha...from the NASDAQ Stock,Market stating that the Corp...licly held shares ("MVPHS") of $1,000,000.,Therefo...
...llis Healthcare,REIT, Inc. today announced the acq...3 healthcare-related properties comprising 20 buil...ortfolio 3 consists of approximately 689,000 squar...of the 13,properties for an approximate gross leas...
...ion with,its second quarter 2008 earnings release ...30), Covance Inc. (NYSE: CVD ) is pleased to invi...nce call that will be broadcast,live over the Inte...y 31, 2008, 9:00 a.m. ET*, Where: http://www.co...
... affect development, researcher says , , T...abies receiving intensive care must undergo numero... to reduce their discomfort, new research suggests...armacological pain therapy. That means about four ...
...archers have demonstrated that the administration ...en sulfide, or H2S the molecule that gives rotten...es survival from extreme blood loss in rats. , Cel...n Robert K. Winn, Ph.D., and colleagues at UW Medi...
Other Medicine News:Health News:SCAN Health Plan Arizona and SCAN Long Term Care Appoints Thomas Lescault President of Arizona Operations 2Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 2Health News:WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market 3Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis 2Health News:Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 3 in Indianapolis 3Health News:Newborns in Intensive Care Often Exposed to Pain 2Health News:Newborns in Intensive Care Often Exposed to Pain 3Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 2Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 3
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB 728 T for HIV AIDS 14909 1Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB 728 T for HIV AIDS 14909 2FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans 6392 1FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans 6392 2Genital Herpes May Never Go Dormant 61659 1Genital Herpes May Never Go Dormant 61659 2Genital Herpes May Never Go Dormant 61659 3
...xpansion of Company,s Phase 3 Study for Wet AMD af...ata, FREMONT, Calif., April 17 NeoVista, Inc. an...ration (FDA) has granted the,company,s request to ...votal Phase 3 trial from 10 to 30 in the United St...ndary to AMD Treated with BEta RadiatioN,Epiretina...
...il 17 Innocoll, Inc., a privately-held,biopharmac...e planned phase,2 clinical trials sponsored by its...d, to investigate CollaRx(R) GENTAMICIN TOPICAL fo...c foot ulcers, has commenced,dosing. CollaRx GENTA...ble,Gentamicin-Collagen Sponge formulated and manu...
Other Medicine Technology:FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4
...edical Professional Diagnostics is a leading provi...e IFA and DFA test menu that includes kits for aut...well as miscellaneous conjugates and components. O...ent of substrates and kit sizes to choose from. Ki...
...edical Professional Diagnostics is a leading provi...e IFA and DFA test menu that includes kits for aut...well as miscellaneous conjugates and components. O...ent of substrates and kit sizes to choose from. Ki...
...edical Professional Diagnostics is a leading provi...e IFA and DFA test menu that includes kits for aut...well as miscellaneous conjugates and components. O...ent of substrates and kit sizes to choose from. Ki...
... of infectious disease ELISA products make us a le...for faster integration into the busy laboratory, o...ased reliability and run-to-run consistency. Our I...ection assays for a wide range of serological assa...
Medicine Products: